scholarly article | Q13442814 |
P356 | DOI | 10.1200/JCO.2011.34.9373 |
P698 | PubMed publication ID | 21632505 |
P50 | author | Peter Lichter | Q2076661 |
Arie Perry | Q37837647 | ||
Stefan M. Pfister | Q39183179 | ||
Andreas von Deimling | Q40381084 | ||
Marc Remke | Q43153350 | ||
Thomas Hielscher | Q87639824 | ||
Michael D. Taylor | Q88072573 | ||
Axel Benner | Q88629706 | ||
Andrey Korshunov | Q89166780 | ||
Andreas E Kulozik | Q89170845 | ||
Paul A Northcott | Q91826566 | ||
Marina Ryzhova | Q97566986 | ||
Wolfram Scheurlen | Q114726761 | ||
Sidney E. Croul | Q114726815 | ||
P2093 | author name string | Hendrik Witt | |
Andrea Wittmann | |||
P433 | issue | 19 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | medulloblastoma | Q1333608 |
adult medulloblastoma | Q18556099 | ||
P304 | page(s) | 2717-2723 | |
P577 | publication date | 2011-05-31 | |
P1433 | published in | Journal of Clinical Oncology | Q400292 |
P1476 | title | Adult medulloblastoma comprises three major molecular variants. | |
P478 | volume | 29 |
Q34457533 | A microRNA-1280/JAG2 network comprises a novel biological target in high-risk medulloblastoma |
Q37365043 | ABC transporter activity linked to radiation resistance and molecular subtype in pediatric medulloblastoma |
Q48011531 | Adolescents and young adults with brain tumors in the context of molecular advances in neuro-oncology |
Q58568139 | Adult Medulloblastoma: Occurrence of a Rare Event |
Q36100967 | Adult medulloblastoma: A rare case report and literature review |
Q55461188 | Adult medulloblastoma: feasibility and effectiveness of utilising high-dose chemotherapy with autologous stem cell rescue in newly diagnosed patients. |
Q48723263 | An adult multifocal medulloblastoma with diffuse acute postoperative cerebellar swelling: immunohistochemical and molecular genetics analysis. |
Q35774418 | An animal model of MYC-driven medulloblastoma |
Q37420196 | BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. |
Q55462417 | Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. |
Q36629427 | Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial |
Q48641521 | Can miRNA-based real-time PCR be used to classify medulloblastomas? |
Q48381540 | Canonical TGF-β pathway activity is a predictor of SHH-driven medulloblastoma survival and delineates putative precursors in cerebellar development |
Q38539478 | Chromosomal heterogeneity and instability characterize pediatric medulloblastoma cell lines and affect neoplastic phenotype |
Q51542148 | Clinicopathological characteristics, molecular subgrouping, and expression of miR-379/miR-656 cluster (C14MC) in adult medulloblastomas. |
Q41573477 | Complete and sustained response of adult medulloblastoma to first-line sonic hedgehog inhibition with vismodegib |
Q37627692 | Cytogenetic prognostication within medulloblastoma subgroups |
Q34330397 | DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis |
Q35896018 | Deep sequencing identifies IDH1 R132S mutation in adult medulloblastoma. |
Q34859989 | Deregulated proliferation and differentiation in brain tumors. |
Q38624646 | Distinctive localization and MRI features correlate of molecular subgroups in adult medulloblastoma. |
Q64078625 | Downregulation of miR-204 expression defines a highly aggressive subset of Group 3/Group 4 medulloblastomas |
Q38194990 | Duration of the pre-diagnostic interval in medulloblastoma is subgroup dependent |
Q91665138 | EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma |
Q45982851 | Early and persisting response to vismodegib in a patient with bone metastasizing medulloblastoma. |
Q28302285 | G-protein coupled receptor expression patterns delineate medulloblastoma subgroups |
Q61446577 | Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells |
Q38629781 | Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype. |
Q37999071 | Insights revealed by high-throughput genomic arrays in nonglial primary brain tumors. |
Q40682183 | Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified Approach |
Q39459649 | Integrating RNA sequencing into neuro-oncology practice. |
Q38671456 | Intertumoral Heterogeneity within Medulloblastoma Subgroups |
Q38120467 | Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma. |
Q46018019 | Long-term outcomes of adult medulloblastoma patients treated with radiotherapy. |
Q35925281 | MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties |
Q90654612 | Magnetic resonance spectroscopy in posterior fossa tumours: the tumour spectroscopic signature may improve discrimination in adults among haemangioblastoma, ependymal tumours, medulloblastoma, and metastasis |
Q38123365 | Management of recurrent medulloblastoma in adult patients: a systematic review and recommendations |
Q91596369 | Medulloblastoma |
Q30040534 | Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations |
Q49938109 | Medulloblastoma in adults : A retrospective single institution analysis |
Q42562593 | Medulloblastoma in adults: they're not just big kids |
Q54954567 | Medulloblastoma in the Molecular Era. |
Q36493799 | Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients? |
Q35099027 | Medulloblastoma subgroups remain stable across primary and metastatic compartments |
Q50604253 | Medulloblastoma: selecting children for reduced treatment. |
Q91826570 | Medulloblastomics revisited: biological and clinical insights from thousands of patients |
Q37469904 | Medulloblastomics: the end of the beginning |
Q53201641 | MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. |
Q37573700 | Molecular Classification of Medulloblastoma |
Q90270316 | Molecular Heterogeneity and Cellular Diversity: Implications for Precision Treatment in Medulloblastoma |
Q64087873 | Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas |
Q36344704 | Molecular markers in pediatric neuro-oncology |
Q38125031 | Molecular neuro-oncology in clinical practice: a new horizon |
Q92865416 | Molecular stratifications, biomarker candidates and new therapeutic options in current medulloblastoma treatment approaches |
Q36977713 | Molecular subgroups of adult medulloblastoma: a long-term single-institution study |
Q35101347 | Molecular subgroups of medulloblastoma |
Q34167499 | Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas |
Q24615271 | Molecular subgroups of medulloblastoma: the current consensus |
Q47827397 | Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). |
Q34369671 | Neuroradiology and histopathology in two cases of adult medulloblastoma |
Q88732919 | Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers |
Q47944360 | Obstacles to Brain Tumor Therapy: Key ABC Transporters |
Q36634407 | Outcomes of adult medulloblastoma treated with a multimodality approach: A tertiary cancer center experience |
Q35944343 | PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma |
Q98191465 | Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma |
Q39159565 | Patterns of care in adult medulloblastoma: results of an international online survey |
Q39382947 | Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma |
Q38689850 | Posterior Fossa Intra-Axial Tumors in Adults |
Q66680444 | Precision Revisited: Targeting Microcephaly Kinases in Brain Tumors |
Q64275194 | Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas |
Q58565636 | Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial |
Q33764662 | Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort |
Q37637737 | Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma |
Q37636027 | Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis |
Q34296928 | Recurrent carotico-cavernous fistula after internal carotid artery ligation: a case with embolization of the fistula via contralateral internal carotid artery approach |
Q53737190 | Refining medulloblastoma subgroups. |
Q88993176 | Rethinking medulloblastoma from a targeted therapeutics perspective |
Q36901551 | Risk stratification of childhood medulloblastoma in the molecular era: the current consensus |
Q36956174 | Signaling pathway and molecular subgroups of medulloblastoma |
Q50744249 | Somatostatin receptor subtype 2 (sst₂) is a potential prognostic marker and a therapeutic target in medulloblastoma. |
Q48651234 | Sonic hedgehog-associated medulloblastoma arising from the cochlear nuclei of the brainstem |
Q36929844 | Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma |
Q37316068 | TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma |
Q38184819 | The 'omics' of adrenocortical tumours for personalized medicine. |
Q35100720 | The G protein α subunit Gαs is a tumor suppressor in Sonic hedgehog-driven medulloblastoma |
Q39662585 | The Neuroradiological Spectra of Adult and Pediatric Medulloblastoma Differ : Results from a Literature-based Meta-analysis |
Q38321654 | The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosis |
Q38126476 | The TP73 complex network: ready for clinical translation in cancer? |
Q36490004 | The WIP1 oncogene promotes progression and invasion of aggressive medulloblastoma variants |
Q38112071 | The adolescent and young adult with cancer: state of the art--brain tumor |
Q38008153 | The clinical implications of medulloblastoma subgroups |
Q96576668 | The clinical treatment and outcome of cerebellopontine angle medulloblastoma: a retrospective study of 15 cases |
Q35946293 | The molecular classification of medulloblastoma: driving the next generation clinical trials |
Q46155460 | The role of angiogenesis in Group 3 medulloblastoma pathogenesis and survival |
Q42647486 | Update on molecular and genetic alterations in adult medulloblastoma |
Q37391485 | Update on the integrated histopathological and genetic classification of medulloblastoma - a practical diagnostic guideline |
Q38053857 | What underlies the diversity of brain tumors? |
Q38673795 | p53 and Meduloblastoma |